



### For Immediate Release

**Contact:**

Miles Tyrer  
American Radiosurgery  
Ph: (858) 451-6173  
Fax: (858) 487-0662  
info@americanradiosurgery.net  
www.americanradiosurgery.net

### **American Radiosurgery forms Strategic Relationship with Deepam Hospitals for Placements of RGS Units in India**

San Diego, CA, September 1, 2012 - American Radiosurgery, Inc. announced today that it has formalized a strategic relationship with Deepam Hospitals based in Chennai, India. Both American Radiosurgery and Deepam Hospitals have agreed to jointly establish cancer treatment centers utilizing the Rotating Gamma Technology of American Radiosurgery, Inc

“Deepam is a rapidly growing hospital chain with significant plans to expand and open new hospitals throughout India. The Hospital chain is particularly impressed with the ability of the RGS Orbiter™ to treat tumors of the brain and the whole body,” said Mr. Ravi Joglekar, the President of American Radiosurgery, Inc. Mr. Joglekar commented further, “This relationship gives American Radiosurgery a foothold in the rapidly expanding Asian radiosurgery market.”

Mr. Ramesh Babu, a spokesperson for the Hospital stated, “Having access to the technological advantages that the RGS Orbiter™ offers over traditional gamma knife systems compelled us to form this relationship. Additionally, the affordable pricing provided by American Radiosurgery makes the establishment of our Cancer Centers feasible.”

Mr. John Clark, CEO of American Radiosurgery added “This is the first of several strategic relationships the company will establish in Asia and we look forward to opening several Cancer Centers with Deepam utilizing our technology.”

American Radiosurgery, Inc., is a neurosurgical/radiosurgical device company providing advanced technology for the non-invasive treatment of brain tumors and other brain disease entities. The company is privately held and based in San Diego, CA.

###

*Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.*